Abstract
Summary
According to our LPI (LP Information) latest study, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size was valued at US$ 1300.3 million in 2023. With growing demand in downstream market, the Duchenne Muscular Dystrophy (DMD) Therapeutics is forecast to a readjusted size of US$ 16430 million by 2030 with a CAGR of 43.7% during review period.
The research report highlights the growth potential of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market. Duchenne Muscular Dystrophy (DMD) Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Duchenne Muscular Dystrophy (DMD) Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Duchenne Muscular Dystrophy (DMD) Therapeutics market.
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
By region, North America has the highest market share, reaching 70.66% in 2019.
Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.
Key Features:
The report on Duchenne Muscular Dystrophy (DMD) Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Duchenne Muscular Dystrophy (DMD) Therapeutics market. It may include historical data, market segmentation by Type (e.g., Exondys, Emflaza), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Duchenne Muscular Dystrophy (DMD) Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Duchenne Muscular Dystrophy (DMD) Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Duchenne Muscular Dystrophy (DMD) Therapeutics industry. This include advancements in Duchenne Muscular Dystrophy (DMD) Therapeutics technology, Duchenne Muscular Dystrophy (DMD) Therapeutics new entrants, Duchenne Muscular Dystrophy (DMD) Therapeutics new investment, and other innovations that are shaping the future of Duchenne Muscular Dystrophy (DMD) Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Duchenne Muscular Dystrophy (DMD) Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Duchenne Muscular Dystrophy (DMD) Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Duchenne Muscular Dystrophy (DMD) Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Duchenne Muscular Dystrophy (DMD) Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Duchenne Muscular Dystrophy (DMD) Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Duchenne Muscular Dystrophy (DMD) Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Duchenne Muscular Dystrophy (DMD) Therapeutics market.
Market Segmentation:
Duchenne Muscular Dystrophy (DMD) Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Exondys
Emflaza
Translarna
Segmentation by application
Hospitals
Clinics
Home Care
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
The research report highlights the growth potential of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market. Duchenne Muscular Dystrophy (DMD) Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Duchenne Muscular Dystrophy (DMD) Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Duchenne Muscular Dystrophy (DMD) Therapeutics market.
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
By region, North America has the highest market share, reaching 70.66% in 2019.
Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.
Key Features:
The report on Duchenne Muscular Dystrophy (DMD) Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Duchenne Muscular Dystrophy (DMD) Therapeutics market. It may include historical data, market segmentation by Type (e.g., Exondys, Emflaza), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Duchenne Muscular Dystrophy (DMD) Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Duchenne Muscular Dystrophy (DMD) Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Duchenne Muscular Dystrophy (DMD) Therapeutics industry. This include advancements in Duchenne Muscular Dystrophy (DMD) Therapeutics technology, Duchenne Muscular Dystrophy (DMD) Therapeutics new entrants, Duchenne Muscular Dystrophy (DMD) Therapeutics new investment, and other innovations that are shaping the future of Duchenne Muscular Dystrophy (DMD) Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Duchenne Muscular Dystrophy (DMD) Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Duchenne Muscular Dystrophy (DMD) Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Duchenne Muscular Dystrophy (DMD) Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Duchenne Muscular Dystrophy (DMD) Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Duchenne Muscular Dystrophy (DMD) Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Duchenne Muscular Dystrophy (DMD) Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Duchenne Muscular Dystrophy (DMD) Therapeutics market.
Market Segmentation:
Duchenne Muscular Dystrophy (DMD) Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Exondys
Emflaza
Translarna
Segmentation by application
Hospitals
Clinics
Home Care
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size 2019-2030
2.1.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Type
2.2.1 Exondys
2.2.2 Emflaza
2.2.3 Translarna
2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
2.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Home Care
2.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
2.5.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2019-2024)
3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Player
3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Players
3.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Duchenne Muscular Dystrophy (DMD) Therapeutics by Regions
4.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth (2019-2024)
4.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth (2019-2024)
4.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth (2019-2024)
5 Americas
5.1 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2019-2024)
5.2 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2019-2024)
5.3 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2019-2024)
6.2 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2019-2024)
6.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics by Country (2019-2024)
7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2019-2024)
7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
10.1.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
10.1.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
10.1.5 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
10.2 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.2.2 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.2.3 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.2.4 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Region (2025-2030)
10.3.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.3.2 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.3.3 Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.3.4 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.3.5 India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.3.6 Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.4.2 France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.4.3 UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.4.4 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.4.5 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.5 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.5.2 South Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.5.3 Israel Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.5.4 Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.5.5 GCC Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Type (2025-2030)
10.7 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Information
11.1.2 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Sarepta Therapeutics Main Business Overview
11.1.5 Sarepta Therapeutics Latest Developments
11.2 PTC Therapeutics
11.2.1 PTC Therapeutics Company Information
11.2.2 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 PTC Therapeutics Main Business Overview
11.2.5 PTC Therapeutics Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Information
11.4.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Bristol-Myers Squibb Main Business Overview
11.4.5 Bristol-Myers Squibb Latest Developments
11.5 Italfarmaco
11.5.1 Italfarmaco Company Information
11.5.2 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Italfarmaco Main Business Overview
11.5.5 Italfarmaco Latest Developments
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Information
11.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Santhera Pharmaceuticals Main Business Overview
11.6.5 Santhera Pharmaceuticals Latest Developments
12 Research Findings and Conclusion